Marion Muehlen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marion Muehlen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Frank P. Mockenhaupt
Institute of International Health, Charité Center for Global Health, Charité—Universitätsmedizin Berlin, Berlin, Germany
1 shared publication - Jonas Schreiber
Institute of Tropical Medicine, Charité, Humboldt University, Berlin, Germany
1 shared publication - Rowland N. Otchwemah
School of Medicine and Health Sciences, University for Development Studies, Tamale, Ghana
1 shared publication - Stephan Ehrhardt
Clinical Department, Bernhard Nocht Institute for Tropical Medicine , Hamburg
1 shared publication Tomas Jelinek
Institute of Tropical Medicine, Charité, Humboldt University, Berlin, Germany
1 shared publicationUlrich Bienzle
Institute of Tropical Medicine, Charité, Humboldt University, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 27 February 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (3) , 361-363
Short Communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana
Summary: Atovaquone‐proguanil has recently been introduced for the treatment and prophylaxis of malaria. However, resistance of Plasmodium falciparum is increasingly reported. We assessed P. falciparum polymorphisms associated with resistance to atovaquone (cytochrome b, cytb) and to cycloguanil, the active compound of proguanil (dihydrofolate reductase, dhfr) in 100 isolates from northern Ghana. None of these exhibited cytb codon 268 mutations. Moreover, no dhfr V16A, S108T or I164L mutations linked with cycloguanil resistance were detected. However, dhfr triple mutants (S108N‐I51L‐C59R) conferring resistance to proguanil and sulphadoxine‐pyrimethamine were seen in 51% of the isolates. In northern Ghana, P. falciparum cytb codon 268 mutations associated with atovaquone resistance are absent. Although proguanil appears to act synergistically with atovaquone in a way different from its antifolate property, the abundance of dhfr polymorphisms will likely compromise the prevention of dissemination of atovaquone‐resistant parasites once emerged.
- 27 February 2004
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (3) , 361-363
Open AccessShort Communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana
Summary: Atovaquone‐proguanil has recently been introduced for the treatment and prophylaxis of malaria. However, resistance of Plasmodium falciparum is increasingly reported. We assessed P. falciparum polymorphisms associated with resistance to atovaquone (cytochrome b, cytb) and to cycloguanil, the active compound of proguanil (dihydrofolate reductase, dhfr) in 100 isolates from northern Ghana. None of these exhibited cytb codon 268 mutations. Moreover, no dhfr V16A, S108T or I164L mutations linked with cycloguanil resistance were detected. However, dhfr triple mutants (S108N‐I51L‐C59R) conferring resistance to proguanil and sulphadoxine‐pyrimethamine were seen in 51% of the isolates. In northern Ghana, P. falciparum cytb codon 268 mutations associated with atovaquone resistance are absent. Although proguanil appears to act synergistically with atovaquone in a way different from its antifolate property, the abundance of dhfr polymorphisms will likely compromise the prevention of dissemination of atovaquone‐resistant parasites once emerged.